Kymera Therapeutics Inc (KYMR)

11:34 AM

Kymera Therapeutics Q3 2025 Earnings Preview - MSN

11:34 AM

10:07 AM

Pattern recognition hints at Kymera Therapeutics Inc. upsideJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com

10:07 AM

08:41 AM

Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus

08:41 AM

07:32 AM

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus

07:32 AM

07:27 AM

How to read the order book for Kymera Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com

07:27 AM

07:14 AM

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

07:14 AM

07:09 AM

Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com Canada

07:09 AM

07:00 AM

Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan

07:00 AM

06:36 AM

How analysts rate Kymera Therapeutics Inc. stock today2025 Year in Review & Stock Portfolio Risk Control - newser.com

06:36 AM

02:57 AM

Is Kymera Therapeutics Inc. stock supported by innovation pipelineEntry Point & Free Verified High Yield Trade Plans - newser.com

02:57 AM

Nov 02, 2025

What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com

Nov 02, 2025

Nov 02, 2025

AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 02, 2025

Nov 01, 2025

34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat

Nov 01, 2025

Nov 01, 2025

Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com

Nov 01, 2025

Nov 01, 2025

Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 01, 2025

Oct 31, 2025

Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

Oct 31, 2025

Oct 30, 2025

Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat

Oct 30, 2025

Oct 30, 2025

How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

Oct 30, 2025

Oct 29, 2025

Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com

Oct 29, 2025

Oct 29, 2025

Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener

Oct 29, 2025

Oct 29, 2025

KYMR insider trade: CEO option exercise and matching share sales - Stock Titan

Oct 29, 2025

Oct 29, 2025

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance

Oct 29, 2025

Oct 28, 2025

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

Oct 28, 2025

Oct 28, 2025

Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - Fundação Cultural do Pará

Oct 28, 2025

Oct 28, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - The Manila Times

Oct 28, 2025

Oct 28, 2025

Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative

Oct 28, 2025

Oct 28, 2025

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan

Oct 28, 2025

Oct 28, 2025

What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará

Oct 28, 2025

Oct 27, 2025

Earnings Recap: Why Kymera Therapeutics Inc. stock could outperform in 2025Trend Reversal & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará

Oct 27, 2025

Oct 27, 2025

Why Kymera Therapeutics Inc. stock could outperform in 2025July 2025 Big Picture & Real-Time Stock Entry Alerts - fcp.pa.gov.br

Oct 27, 2025

Oct 27, 2025

Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis - TipRanks

Oct 27, 2025

Oct 27, 2025

Kymera’s IRF5 degrader shows promise in preclinical lupus, RA studies - Investing.com

Oct 27, 2025

Oct 27, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Investing News Network

Oct 27, 2025

Oct 27, 2025

Kymera (NASDAQ: KYMR) shows KT-579 IRF5 degrader activity in lupus, RA at ACR - Stock Titan

Oct 27, 2025

Oct 26, 2025

Kymera Therapeutics (NASDAQ:KYMR) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat

Oct 26, 2025